text stringlengths 198 2.89k |
|---|
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
capital and other general corporate purposes.
Mirati Collaboration
. In October 2022, we entered into a collaboration and supply agreement with Mirati Therapeutics, Inc. (“Mirati”) to evaluate th... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
and recommended Phase 2 dose for the combination of adagrasib and FYARRO in patients with KRAS
G12C-
mutant solid tumors. In addition, the study will investigate the safety, tolerability and effic... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
license agreement, dated November 15, 2019, as amended August 31, 2021 (the “BMS License Agreement”) with Abraxis BioScience, LLC, a wholly owned subsidiary of Celgene Corporation, which is a wholly... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
under this agreement were paid during the year ended December 31, 2022. See Note 9 to the consolidated financial statements for more information about the BMS License Agreement.
Under the terms of ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
on the third anniversary of the effective time of such 2021 PIPE Financing plus any accrued and unpaid interest due thereon.
EOC License Agreement
In December 2020, we entered into the EOC License... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
of license expense in the fourth quarter of 2020 and had a corresponding $2.8 million sublicense payable to BMS on the balance sheet as of December 31, 2020, which was paid in 2021.
During the four... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
2022, we received written notice from EOC that EOC has elected to terminate the EOC License Agreement, effective immediately. On June 27, 2022, EOC filed a Request for Arbitration with the Internati... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
will continue to be impacted by a number of challenging global and national events and circumstances that continue to evolve, including the COVID-19 pandemic, extreme weather conditions, increased e... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
warranted, to minimize any potential negative impacts on our business resulting from these events and circumstances. For example, as the COVID-19 pandemic has developed, we have taken numerous steps... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
chip manufacturers, which led to extended lead times for FYARRO and diversion of certain lab materials needed to support COVID-19 relief efforts. While certain of these disruptions have been resolve... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
the closure of offices, lack of resources or closure of borders, among other measures being put in place around the world and we made certain modifications to employee travel, with masking and vacci... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
employees and other third parties with whom we do business. At this point, the extent to which these global or national events and circumstances may affect our future business, operations and develo... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
”), and Aadi Subsidiary, Inc. (formerly known as Aadi Bioscience, Inc. (“Private Aadi”)); and (ii) a subscription agreement (“Subscription Agreement”) with certain investors (the “2021 PIPE Investors... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
(the “Merger”);
in connection with and immediately prior to the Merger, we effected a reverse stock split of our common stock at a ratio of 15:1 and changed our name from “Aerpio Pharmaceuticals, I... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
issory notes outstanding immediately prior to the Effective Time;
at the closing of the Merger, we assumed all of the outstanding and unexercised options to purchase shares of Private Aadi common st... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
and 29.2%, respectively, of our outstanding common stock on a fully-diluted basis; and
we entered into a contingent value rights agreement (“CVR Agreement”) pursuant to which each of our stockholde... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
R Agreement). The CVR Agreement automatically terminated effective July 24, 2022, the date the Gossamer License Agreement terminated.
Key Trends and Factors Affecting Comparability Between Periods
... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
and administrative expenses for the year ended December 31, 2022. We expect these expenses will continue to increase in 2023, as compared to 2022, with the ongoing commercialization of FYARRO and pr... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
SEC and those of the Nasdaq Capital Market (“Nasdaq”), (ii) legal, accounting and other professional services, (iii) insurance, (iv) investor relations activities, and (v) other administrative and p... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
connection with research and development activities, selling, general and administrative costs associated with our operations, and costs associated with the Merger. We expect to continue to incur si... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
of the consolidated balance sheets and statements of operations and comprehensive loss presented herein. The following discussion and analysis are based on our consolidated financial statements cont... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
recorded at the net sales price, which includes provisions for the following allowances which are reflected either as a reduction to the related account receivable or as an accrued liability, depend... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
contracted or statutory discount rates and expected utilization by benefit plan participants. Our estimates for expected utilization of rebates are based on utilization data received from the SDs an... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
and the discounted price paid to the SDs and SP by these entities. If actual future chargebacks vary from these estimates, we may need to adjust prior period accruals, which would affect product sal... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
istent with industry practice, we offer the SDs and SP limited product return rights for damages, shipment errors, and expiring product, provided that the return is within a specified period around t... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
Grant revenue is derived from federal grants, primarily with the FDA. We have determined that the government agencies providing grants to us are not customers. Grant revenue is recognized when ther... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in the accompanying statements of operations and co... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
being a public company that we did not incur as a privately-held company, including (i) costs to comply with the rules and regulations of the SEC and those of Nasdaq, (ii) legal, accounting and othe... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
(iii) external costs of outside consultants who assist with technology development, regulatory affairs, clinical development and quality assurance; (iv) payments made under our third-party licensing... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
RO in additional indications and any other product candidates we may develop in the future and expand our product candidate pipeline.
The process of commercialization and conducting the necessary pr... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
ended December 31, 2021, we recognized an impairment of $74.2 million to bring the carrying amount of the contract intangible asset down to its estimated fair value of $3.9 million at August 26, 202... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
product for sales subsequent to the FDA approval in November 2021. Costs incurred prior to the FDA approval were expensed when incurred
108
Table of Contents
Other Income, Net
Other income, net ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
benefits for the net losses we have incurred in each year or our earned tax credits, due to our uncertainty of realizing a benefit from those items.
Results of Consolidated Operations:
The followi... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
Total operating expenses
77,897
112,337
Loss from operations
(62,681)
(111,217)
Other income, net
2,168
1,129
Loss before income tax expense
(60,513)
(110,088)
Income tax expense
(2)
Ne... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
year ended December 31, 2021.
License Revenue
During the year ended December 31, 2021, we recognized $1.0 million of revenue upon achieving the FDA approval milestone from EOC Pharma as considerat... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
period for eligible grant reimbursement with the FDA ended during the
year ended December 31, 2021
. There were no new grants during the
year ended
December 31, 2022
109
Table of Contents
Ope... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
to support future launches:
$13.4 million in personnel related expenses due to increased headcount, incentive bonuses and share-based compensation. Sales and administrative headcount increased to 3... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
,458
External clinical development
8,347
5,838
Clinical drug product manufacturing
818
6,646
Other expense
428
369
Total research and development expense
32,662
19,670
Research and devel... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
related to clinical drug product manufacturing.
Cost of Goods Sold
Cost of goods sold was $1.3 million reflecting primarily royalties incurred on product sold during the year ended
December 31, 20... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
2022.
During the year ended December 31, 2021, we recorded a $74.2 million impairment charge to reduce the carrying value of the intangible asset to its fair value to $3.9 million at the Effective ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
168
1,129
Other income, net for the
year ended
December 31, 2022
, was
$2.2 million of income, compared to $1.1 million of income for the year ended
December 31, 2021
. The change was primari... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
idity and Capital Resources
Overview
As of December 31, 2022, we had $172.6 million of cash, cash equivalents and short-term investments. Prior to and a
s of the date of filing this Annual Report ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
of $203.2 million. Our net losses were $60.5 million and $110.1 million for the years ended December 31, 2022 and 2021, respectively. These losses have resulted principally from costs incurred in co... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
and the potential for losses, to increase substantially as we conduct clinical trials of FYARRO, in additional indications and seek to expand our pipeline.
From inception through December 31, 2022,... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
a Sales Agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”), with respect to an “at the market offering” pursuant to which we may offer and sell, from time to time at our sole di... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
each sale of shares of common stock under the Sales Agreement.
As of December 31, 2022, no shares of common stock had been sold under the Sales Agreement.
The shares of our common stock to be offe... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
million of common stock, preferred stock, debt securities, warrants, or units comprised of any combination of these securities, for our own account in one or more
111
Table of Contents
offerings.... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
Company’s common stock for a price of $12.50 per share and Pre-Funded Warrants to purchase an aggregate of 2,426,493 shares of the Company's common stock, at a purchase price of $12.4999 per Pre-Fun... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
2
2021
Net cash used in operating activities
(49,640)
(22,423)
Net cash (used in) provided by investing activities
(132,886)
25,153
Net cash provided by financing activities
72,620
141,804
... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
advanced malignant PEComa, advance and support FYARRO in additional indications in the clinic, develop new product candidates, and other operating and general administrative activities, including op... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
expense, the impairment of the contract intangible asset, and depreciation and amortization expense.
For the year ended December 31, 2021, cash used in operating activities was $22.4 million and re... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
of short-term investments $145.2 million, offset by maturities of $12.8 million.
Cash provided by investing activities for the year ended December 31, 2021 related to cash acquired in connection wi... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
PIPE Financing.
Cash provided by financing activities for the year ended December 31, 2021 includes $155.0 million gross cash proceeds from our 2021 PIPE Financing and $0.8 million from exercise of... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
isades and Morristown leases was $0.4 million and $0.2 million for the years ended December 31, 2022 and 2021, respectively. See Note 8 to the consolidated financial statements for details related to... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
enius Agreement contains specific activities such as non-cancellable commitments, minimum purchase commitments, and binding annual forecasts. Under the Fresenius Agreement, which is effective through... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
also have contracts with various organizations to conduct research and development activities, including clinical trial organizations to manage clinical trial activities and manufacturing companies ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
revenues and expenses during the periods presented. We believe that the estimates, judgments and assumptions are reasonable based upon information available to us at the time that these estimates, j... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
for these transactions, and we record net product sales when control is transferred to the customer, which occurs upon receipt by the customer. The transaction price for net product sales represents... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
current information. These estimates involve a substantial degree of judgment, in particular, for government-mandated rebates and chargebacks, such as for the Medicaid and 340B programs.
Research a... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
estimation of accruals for services rendered by CROs and other vendors in connection with clinical trials. We record the estimated costs of research and development activities based upon the estimat... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
service providers. We make significant judgments and estimates in determining the accrued liabilities and prepaid expense balances in each reporting period. As actual costs become known, we adjust o... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
to be performed, we modify our estimates of accrued expenses accordingly on a prospective basis.
Share-Based Compensation
We recognize all share-based payments to employees, including grants of em... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
oupon U.S. treasury notes with maturities approximately equal to the expected term of the stock options and (iv) expected dividends.
Options granted during the year have a maximum contractual term o... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
companies that are most representative of us.
We have limited historical stock option activity and therefore estimate the expected term of stock options granted to employees, officers, and director... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
grant date fair value over the associated service period of the award, which is generally the vesting term. For the years ended
114
Table of Contents
December 31, 2022 and 2021, we recognized sha... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
period of 2.7 years. The intrinsic value of all out
standing stock options as of December 31, 2022 w
as
$2.8 million.
Merger and Acquired Contractual Intangible Asset
Aerpio issued common stock... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
seven (7) members of the board of directors of the Company post-Merger were composed of directors designated by Private Aadi under the terms of the Merger Agreement, and one (1) member of the board ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
the holders of Private Aadi collectively owned immediately following the Merger and they are not considered to be a single voting group; and (v) following the Merger, the Company is headquartered in... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
group of assets is acquired. A business is defined in ASC 805, Business Combinations, as an integrated set of inputs and processes that are capable of generating outputs that have the ability to pro... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
intangible asset related to Aerpio’s license agreement with Gossamer Bio. Inc., under which 90% of any future net cash proceeds will be remitted to CVR Holders and paid through the CVRs. In accordan... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
to be less than the excess purchase price of the fair value of the acquired assets and liabilities ascribed to the acquired contract intangible asset. As a result, we performed a valuation of the ac... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
the event of certain development and commercialization milestones and sales-based royalties. Our fair value determination of the intangible asset utilized a
115
Table of Contents
scenario-based, ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
.
Application of the Monte Carlo simulation model in valuing the potential sales-based milestone and royalties involves making assumptions for (a) the probability of clinical success determined with... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
a weighted-average cost of capital, revenue volatility and asset volatility.
Recent Accounting Pronouncements
See Note 2 to the consolidated financial statements for a discussion of recent account... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
, PCAOB ID#243)
118
Consolidated Balance Sheets as of December 31, 2022 and 2021
120
Consolidated Statements of Operations for the Years ended December 31, 2022 and 2021
121
Consolidated Statem... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
Accounting Firm
To the Stockholders and the Board of Directors
Aadi Bioscience, Inc.
Pacific Palisades, California
Opinion on the Consolidated Financial Statements
We have audited the accompany... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
the results of its operations and its cash flows for the years then ended
in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These cons... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Aadi Bioscience, Inc. is not required to have, nor were we engaged to perform, an audi... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
accounts or disclosures to which it relates.
Product Revenue Allowances for Chargebacks and Government Rebates
As described in Note 2 to the consolidated financial statements, revenue from product... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
. The principal consideration that led to our determination is the judgement required to evaluate the estimated government rebates and chargebacks that will be processed based upon the limited perio... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
-end.
118
Table of Contents
/s/ BDO USA, LLP
We have served as the Company’s auditor since 2017
San Diego, California
March 28, 2023
119
Table of Contents
AADI BIOSCIENCE, INC.
Consolidated... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
and equipment, net
508
57
Operating lease right-of-use assets
1,522
557
Intangible asset, net
3,811
Other assets
2,178
2,213
Total assets
184,237
157,910
Liabilities and stockholders’ ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
ments and contingencies (Note 16)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2022 and 2021
Common s... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
406
Total liabilities and stockholders’ equity
184,237
157,910
The accompanying notes are an integral part of these consolidated financial statements.
120
Table of Contents
AADI BIOSCIENCE, IN... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
acquired contract intangible asset
3,724
74,156
Total operating expenses
77,897
112,337
Loss from operations
(62,681)
(111,217)
Other income (expense)
Change in fair value of convertible p... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
(60,513)
(110,737)
Net loss per share attributable to common stockholders, basic and diluted
(2.69)
(12.41)
Weighted average number of common shares outstanding used in computing net loss per sh... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
,628)
(110,090)
The accompanying notes are an integral part of these consolidated financial statements.
122
Table of Contents
AADI BIOSCIENCE, INC.
Consolidated Statements of Stockholders’ Equi... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
common stock upon exercise of stock options
73
833
833
Issuance of common stock to PIPE Investors, net of issuance costs
11,853
145,383
145,384
Issuance of common stock to former stockholder... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
)
Net loss
(110,090)
(110,090)
Balance at December 31, 2021
20,895
279,089
(142,685)
136,406
Issuance of common stock upon exercise of stock options
132
401
401
Issuance of common stock ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
at December 31, 2022
24,435
361,689
(115)
(203,198)
158,378
The accompanying notes are an integral part of these consolidated financial statements.
123
Table of Contents
AADI BIOSCIENCE, IN... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
-term investments, net
(1,215)
Change in fair value of convertible promissory notes
(1,585)
Non-cash interest expense
665
Gain upon extinguishment of debt
(196)
Non-cash lease expense
382
1... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
used in operating activities
(49,640)
(22,423)
Investing activities:
Purchases of property and equipment
(444)
(46)
Purchases of short-term investments
(145,192)
Maturities of short-term in... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
of common stock upon exercise of warrants
55
Deferred offering costs paid for financing
(337)
Costs incurred in connection with issuance of common stock
(322)
(9,617)
Proceeds from the issuan... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
.
124
Table of Contents
AADI BIOSCIENCE, INC.
Consolidated Statements of Cash Flows (continued)
(Amounts in thousands)
Year Ended December 31,
2022
2021
Supplemental disclosure of cash flow ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
an integral part of these consolidated financial statements.
125
Table of Contents
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Nature of Organization and Operations
Aadi Bioscience, Inc. (tog... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
Administration (the “FDA”) approved FYARRO sirolimus protein-bound particles for injectable suspension (albumin-bound) for the treatment of adult patients with locally advanced unresectable or metas... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
Aerpio Pharmaceuticals, Inc. and Name Change
On May 16, 2021, the Company, then operating as Aerpio Pharmaceuticals, Inc. (“Aerpio”), entered into the Agreement and Plan of Merger (“Merger Agreemen... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
as a wholly owned subsidiary of Aerpio (the “Merger”), (ii) Aerpio changed its name to Aadi Bioscience, Inc. in connection with and immediately prior to the Effective Time, and (iii) Aerpio effected... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.